about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

While PhI­II Parkin­son's tri­als go slow­er than ex­pect­ed, Cerev­el pre­views plans to raise $900M

3 years ago
Financing
R&D

Supreme Court toss­es Bris­tol My­er­s' bid to re­vive $1.2B CAR-T case against Gilead

3 years ago
Cell/Gene Tx
Law

With all hands on deck for lead sick­le cell tri­al, Beam pulls back clin­i­cal plans for sec­ond base edit­ing ther­a­py

3 years ago
R&D
Cell/Gene Tx

GSK re­ports PhI­II flop for BC­MA drug — rais­ing ques­tions about its fu­ture and up­ping the stakes on com­bos

3 years ago
R&D

Lat­est news on pa­tient death in n-of-1 CRISPR tri­al; Good news for RSV; Vac­cine R&D rev­o­lu­tion; and more

3 years ago
Weekly

Sanofi, As­traZeneca clinch first OK for RSV an­ti­body — just as vac­cines line up at reg­u­la­tors

3 years ago
Pharma
FDA+

'Do the right thing': Bil­lion­aire push­es strug­gling biotech to re­turn cash to in­vestors

3 years ago
People

Up­dat­ed: GSK nabs pri­or­i­ty re­view on RSV vac­cine, kicks off show­down with Pfiz­er — while 'set­ting the bar high' on ...

3 years ago
R&D
Pharma

CFIUS re­view trig­gers de­lay on F-star's sale to Chi­nese play­er

3 years ago
Deals
China

Ex­elix­is shells out $100M cash in a pair of deals, shoot­ing for dif­fer­ent takes on CD47, AD­Cs

3 years ago
Deals

Covid-19 spurred a his­toric vac­cine R&D ef­fort. What does it mean for fu­ture pan­demics?

3 years ago
R&D
Coronavirus

Pfiz­er de­clares 'first-ever' PhI­II win for RSV vac­cine in in­fants — and it's steer­ing straight to FDA

3 years ago
R&D

Ther­mo Fish­er wa­gers on ear­ly can­cer di­ag­nos­tics in $2.6B cash deal for mul­ti­ple myelo­ma test mak­er

3 years ago
Deals
Diagnostics

Ab­b­Vie dis­cards PhI­Ib au­toim­mune drug from 10-year-old dis­cov­ery pact, cit­ing chron­ic tox­i­col­o­gy study

3 years ago
R&D

Changes afoot at GSK; The first vic­tim of IRA?; As work halts, fam­i­lies be­hind gene ther­a­py seek con­trol; and more

3 years ago
Weekly

Tak­ing on Big Phar­ma ri­vals, biotech start­up un­veils first-in-hu­man da­ta on ROS1 drug

3 years ago
R&D

Black­stone in­vests $50M in PTC, lines up $1B loan to sup­port deal­mak­ing

3 years ago
Financing

As 'low­er than pro­ject­ed' da­ta send it back to the draw­ing board, Sanofi takes $1.6B hit on IL-2

3 years ago
R&D
Pharma

‘Un­like­ly to trans­form pa­tient care’: GSK punts top late-stage drug af­ter PhI­II da­ta dis­ap­point

3 years ago
R&D

As­traZeneca spot­lights pos­i­tive PhII, PhI­II read­out for a pair of next-gen breast can­cer drugs

3 years ago
R&D

CEPI teams up with Ko­re­an vac­cine mak­er in $140M pact to scale up its nascent mR­NA plat­form

3 years ago
Deals

Ex-Genen­tech sci­en­tist sen­tenced to six months in prison for steal­ing trade se­crets

3 years ago
People
Pharma

Pre­lude to buy­out? Astel­las picks up Taysha stock, two gene ther­a­py pro­grams for $50M

3 years ago
Deals
Cell/Gene Tx

No­var­tis takes an­oth­er stride to­ward Alex­ion's turf with PhI­II PNH win

3 years ago
R&D
First page Previous page 21222324252627 Next page Last page
A service from the Financial Times